Table 3.
Adjusted1) associations of 10 cytokine polymorphisms with elevated serum levels of total IgE in the ECRHS-Basel Study.
| Elevated total IgE cases2) | |||||
| Genotype | cases/controls3) | Odds Ratio | 95% Conficence Interval | P-value | |
| IL4 (-589C>T) | CC | 69/227 | 1 | -- | -- |
| CT | 25/81 | 1 | 0.57 – 1.65 | 0.91 | |
| TT | 7/6 | 3.89 | 1.24 – 12.15 | 0.02 | |
| IL4R Q576R (A>G) | AA | 67/194 | 1 | -- | -- |
| AG | 30/105 | 0.91 | 0.55 – 1.50 | 0.71 | |
| GG | 4/9 | 1.31 | 0.38 – 4.51 | 0.67 | |
| IL6(-174G>C) | GG | 34/98 | 1 | -- | -- |
| GC | 49/151 | 0.91 | 0.54 – 1.52 | 0.71 | |
| CC | 18/62 | 0.80 | 0.41 – 1.56 | 0.52 | |
| IL10 (-1082G>A) | GG | 35/112 | 1 | -- | -- |
| GA | 54/137 | 1.22 | 0.74 – 2.01 | 0.44 | |
| AA | 12/64 | 0.55 | 0.27 – 1.16 | 0.12 | |
| IL10 (-819C>T) | CC | 44/180 | 1 | -- | -- |
| CT | 48/112 | 1.81 | 1.12 – 2.92 | 0.02 | |
| TT | 9/20 | 1.96 | 0.82 – 4.67 | 0.13 | |
| IL12p40(1188A>C) | AA | 61/183 | 1 | -- | -- |
| AC | 39/112 | 1.03 | 0.64 – 1.66 | 0.89 | |
| CC | 1/18 | 0.16 | 0.02 – 1.20 | 0.08 | |
| IL13 R130Q (A>G) | GG | 68/206 | 1 | -- | -- |
| GA | 28/96 | 0.82 | 0.49 – 1.37 | 0.46 | |
| AA | 5/9 | 2.14 | 0.67 – 6.78 | 0.19 | |
| IL18(-137G>C) | GG | 43/163 | 1 | -- | -- |
| GC | 42/127 | 1.22 | 0.75 – 2.00 | 0.42 | |
| CC | 16/24 | 2.51 | 1.21 – 5.20 | 0.01 | |
| TNF(-308G>A) | GG | 66/220 | 1 | -- | -- |
| GA | 33/85 | 1.41 | 0.86 – 2.32 | 0.17 | |
| AA | 2/7 | 1.18 | 0.23 – 5.98 | 0.84 | |
| CD14 (-159C>T) | CC | 24/88 | 1 | -- | -- |
| CT | 55/140 | 1.44 | 0.83 – 2.52 | 0.19 | |
| TT | 21/79 | 0.97 | 0.50 – 1.90 | 0.94 | |
1) Adjusted for age and gender.
2) Elevated total IgE cases had serum IgE level >100 kU/L, measured by CAP system (Pharmacia Diagnostics). Controls had IgE = 100 kU/L.
3) Controls had IgE = 100 kU/L